About Arsanis (NASDAQ:ASNS)
Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. Its lead product candidate is ASN100, a first-in-class mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia. The company's preclinical pipeline comprises mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ASNS
CUSIPN/A
Phone781-819-5704
Debt
Debt-to-Equity Ratio0.17%
Current Ratio7.45%
Quick Ratio7.45%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.29 per share
Price / Book3.69
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees40
Outstanding Shares14,290,000
Arsanis (NASDAQ:ASNS) Frequently Asked Questions
What is Arsanis' stock symbol?
Arsanis trades on the NASDAQ under the ticker symbol "ASNS."
How were Arsanis' earnings last quarter?
Arsanis (NASDAQ:ASNS) announced its earnings results on Friday, March, 9th. The company reported ($1.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by $0.83. View Arsanis' Earnings History.
What price target have analysts set for ASNS?
4 brokers have issued twelve-month price targets for Arsanis' shares. Their predictions range from $23.00 to $27.00. On average, they anticipate Arsanis' share price to reach $25.3333 in the next year. View Analyst Ratings for Arsanis.
Who are some of Arsanis' key competitors?
Some companies that are related to Arsanis include La Jolla Pharmaceutical (LJPC), Coherus BioSciences (CHRS), Novavax (NVAX), Jounce Therapeutics (JNCE), Heska (HSKA), Voyager Therapeutics (VYGR), Fate Therapeutics (FATE), EntreMed (CASI), Mesoblast (MESO), BioCryst Pharmaceuticals (BCRX), PDL Biopharma (PDLI), Solid Biosciences (SLDB), Vericel (VCEL), Nightstar Therapeutics (NITE) and Agenus (AGEN).
Who are Arsanis' key executives?
Arsanis' management team includes the folowing people:
- Dr. Tillman U. Gerngross Ph.D., Co-Founder & Chairman (Age 54)
- Dr. Rene Russo Pharm.D, BCPS, Pres, CEO & Director (Age 43)
- Mr. Michael P. Gray MBA, CPA, CFO & COO (Age 47)
- Dr. Anthony Christopher Stevens M.D., Chief Medical Officer (Age 59)
- Dr. Eszter Nagy M.D., Ph.D., Co-Founder, Chief Scientific Officer & Director (Age 52)
When did Arsanis IPO?
(ASNS) raised $50 million in an initial public offering on Thursday, November 16th 2017. The company issued 3,100,000 shares at a price of $15.00-$17.00 per share. Citigroup, Cowen and Piper Jaffray served as the underwriters for the IPO.
When does the company's lock-up period expire?
Arsanis' lock-up period expires on Tuesday, May 15th. Arsanis had issued 4,000,000 shares in its public offering on November 16th. The total size of the offering was $40,000,000 based on an initial share price of $10.00. After the expiration of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.
Has Arsanis been receiving favorable news coverage?
Press coverage about ASNS stock has trended somewhat positive this week, Accern reports. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Arsanis earned a media sentiment score of 0.09 on Accern's scale. They also assigned media stories about the company an impact score of 45.38 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of Arsanis?
Shares of ASNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arsanis' stock price today?
One share of ASNS stock can currently be purchased for approximately $15.85.
How big of a company is Arsanis?
Arsanis has a market capitalization of $221.71 million. The company earns $-33,870,000.00 in net income (profit) each year or ($16.23) on an earnings per share basis. Arsanis employs 40 workers across the globe.
How can I contact Arsanis?
Arsanis' mailing address is 890 WINTER STREET SUITE 230, WALTHAM MA, 02451. The company can be reached via phone at 781-819-5704 or via email at [email protected]
MarketBeat Community Rating for Arsanis (ASNS)
MarketBeat's community ratings are surveys of what our community members think about Arsanis and other stocks. Vote "Outperform" if you believe ASNS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASNS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Arsanis (NASDAQ:ASNS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Arsanis in the last 12 months. Their average twelve-month price target is $25.3333, suggesting that the stock has a possible upside of 59.83%. The high price target for ASNS is $27.00 and the low price target for ASNS is $23.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | N/A |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | N/A |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $25.3333 | $25.3333 | $25.00 | N/A |
| Price Target Upside: | 59.83% upside | 5.07% upside | 78.95% upside | N/A |
Arsanis (NASDAQ:ASNS) Consensus Price Target History
Arsanis (NASDAQ:ASNS) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
Arsanis (NASDAQ:ASNS) Earnings History and Estimates Chart
Arsanis (NASDAQ:ASNS) Earnings Estimates
Current Year EPS Consensus Estimate: $-4.57 EPS
Next Year EPS Consensus Estimate: $-5.36 EPS
Arsanis (NASDAQ ASNS) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 3/9/2018 | Q4 2017 | ($0.8550) | ($1.68) | | | View | N/A |  |
(Earnings results data provided by Zacks Investment Research)
Arsanis (NASDAQ:ASNS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Arsanis (NASDAQ ASNS) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 69.45%
Arsanis (NASDAQ ASNS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/20/2017 | Polaris Venture Management Co. | Major Shareholder | Buy | 500,000 | $10.00 | $5,000,000.00 | | |
| 11/20/2017 | Tillman U Gerngross | Director | Buy | 200,000 | $10.00 | $2,000,000.00 | | |
(Data available from 1/1/2013 forward)
Arsanis (NASDAQ ASNS) News Headlines
| Source: |
|
Arsanis (NASDAQ:ASNS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Arsanis (NASDAQ:ASNS) Income Statement, Balance Sheet and Cash Flow Statement
Arsanis (NASDAQ ASNS) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
